A study published by The BMJ found that many cancer drugs approved by the European Medicines Agency between 1995 and 2020 lack proof of added benefit, especially those approved through expedited pathways. Despite claims by the pharmaceutical industry about high drug prices being necessary for research and development costs, more than half of these drugs recover R&D expenses within three years. The study highlights concerns about the misalignment of incentives in the pharmaceutical market with patient needs and calls for better alignment between regulatory and reimbursement processes to ensure the development of effective drugs for patients with significant needs.
Source link
Significant proportion of cancer drugs lack proof of added benefit, finds study
